Pharmacokinetics of Ropivacaine for Combined Lumbar Plexus-sciatic nerve Blockade<?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /> 肖洁 王祥瑞 蔡美华 杭燕南 孙大金 Jie XIAO,Xiangrui WANG ,Meihua CAI ,Dajin SUN . Department of Anesthesiology, Renji Hospital, Shanghai Second Medical University, Shanghai 200127 CHINA Abstract Objective:A RP-HPLC method for determination of ropivacaine in plasma was developed, and the pharmacokinetics of ropivacaine was investigated in combined lumbar plexus-sciatic nerve blockade. Methods:8 patients undergoing lower-extremity surgery accepted combined lumbar plexus-sciatic nerve block, 0.375% ropivacaine 3mg/kg was injected. Blood samples were taken before the operation and at 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 180, 240, 360, 720 and 1440min after drug administration for determination of plasma ropivacaine concentration. Agilent Zorbax SB-C18(4.6×250mm,5μm)as a stationary phase and the pharmacokinetic parameters were calculated by 3P97. Results:The linear range was from 10ng/ml ~8000ng/ml, the AUFS is 1ng/ml, and the pharmacokinetic parameters are Cmax13.09±0.89mg/l,Cmax23.84±1.58mg/l,t1/2Kα7.56±4.65min,t1/2β890.3±365.8min. Conclusion:A RP-HPLC is a stable, simple and sensitive methord for determination of plasma ropivacaine concentration during combined lumbar plexus-sciatic never blockade. Key Words:Ropivacaine; Combined lumbar plexus-sciatic nerve block; Pharmacokinetics 腰丛-坐骨神经阻滞有麻醉操作简单,对机体的影响小,麻醉后并发症少及术后镇痛时间长等特点,因此近几年来受到临床的广泛重视。罗比卡因作为一种新型长效的酰胺类局麻药,对中枢神经系统和心血管系统毒性低[1],已成为神经阻滞的常用药物,但神经阻滞时用药量大,甚至超过用药极限量。本研究旨在建立一种反相高效液相色谱分析法,用于测定腰丛-坐骨神经阻滞后盐酸罗比卡因的血药浓度,计算该药在人体内药代动力学参数,为临床安全用药提供参考。 |